| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Department of Tumor Progression and Metastasis, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; 2 Department of General Surgical Science (Department of Surgery I), Graduate School of Medical Sciences, Gunma University, Gunma, Japan; 3 Department of Otolaryngology and Sensory Organs, Osaka University Graduate School of Medicine, Osaka, Japan; 4 Department of Urology, School of Medicine, University of Tokushima, Tokushima, Japan; and 5 Department of Biochemistry, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Requests for reprints: Avraham Raz, Tumor Progression and Metastasis Program, Karmanos Cancer Institute, Wayne State University, 110 East Warren Avenue, Detroit, MI 48201. Phone: 313-833-0715; Fax: 313-831-7518; E-mail: raza{at}kci.wayne.edu.
Galectin-3 (gal-3), a member of the ß-galactosidebinding proteins family, was identified as a binding partner of ß-catenin. Analysis of the human gal-3 sequence reveled a structural similarity to ß-catenin as it also contains the consensus sequence (S92XXXS96) for glycogen synthase kinase-3ß (GSK-3ß) phosphorylation and can serve as its substrate. In addition, Axin, a regulator protein of Wnt that complexes with ß-catenin, also binds gal-3 using the same sequence motif identified here by a deletion mutant analysis. The data presented here give credence to the suggestion that gal-3 is a key regulator in the Wnt/ß-catenin signaling pathway and highlight the functional similarities between gal-3 and ß-catenin.
This article has been cited by other articles:
![]() |
S. Song, N. Mazurek, C. Liu, Y. Sun, Q. Q. Ding, K. Liu, M.-C. Hung, and R. S. Bresalier Galectin-3 Mediates Nuclear {beta}-Catenin Accumulation and Wnt Signaling in Human Colon Cancer Cells by Regulation of Glycogen Synthase Kinase-3{beta} Activity Cancer Res., February 15, 2009; 69(4): 1343 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Eude-Le Parco, G. Gendronneau, T. Dang, D. Delacour, V. L Thijssen, W. Edelmann, M. Peuchmaur, and F. Poirier Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice Glycobiology, January 1, 2009; 19(1): 68 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Weinberger, B.-L. Adam, C. G. Gourin, W. H. Moretz III, R. J. Bollag, B. Y. Wang, Z. Liu, J. R. Lee, and D. J. Terris Association of Nuclear, Cytoplasmic Expression of Galectin-3 With beta-Catenin/Wnt-Pathway Activation in Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 503 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakahara, N. Oka, Y. Wang, V. Hogan, H. Inohara, and A. Raz Characterization of the nuclear import pathways of galectin-3. Cancer Res., October 15, 2006; 66(20): 9995 - 10006. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mazurek, Y. J. Sun, J. E. Price, L. Ramdas, W. Schober, P. Nangia-Makker, J. C. Byrd, A. Raz, and R. S. Bresalier Phosphorylation of Galectin-3 Contributes to Malignant Transformation of Human Epithelial Cells via Modulation of Unique Sets of Genes Cancer Res., December 1, 2005; 65(23): 10767 - 10775. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |